Product logins

Find logins to all Clarivate products below.


Aliaksei Holik

Director for Discovery and Translational Science Consulting

Aliaksei is a biomedical scientist with over 15 years of experience in research, specializing in the use of computational biology and machine learning to unravel disease mechanisms, identify and validate therapeutic targets, and prioritize patient populations most likely to benefit from these therapies. With a strong background in Molecular Biology and Genetics, he has utilized a wide array of omics technologies throughout the entire research lifecycle, from experimental design and data generation to analysis and translating results into actionable insights.

As Director for Discovery and Translational Science Consulting Services, Aliaksei assists clients, ranging from top pharmaceutical companies to stealth-mode biotechs in their drug discovery and translational research efforts. His support encompasses data curation, management, and analytics services applied to pre-clinical and clinical datasets in order to understand disease and drug action mechanisms, prioritize targets and indications, and identify molecular and clinical biomarkers to pinpoint patient populations with the most favourable response and safety profiles.

Aliaksei holds a PhD in Cancer Biology from Cardiff University and a BSc in Molecular Biology from the University of Edinburgh.

Latest news

News November 6, 2025
Fujifilm Selects IPfolio from Clarivate

Maximizing the value of intellectual property assets to support business growth London, U.K. November 6, 2025. Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that…

News October 30, 2025
Clarivate Pulse of the Library Report Reveals Link Between AI Literacy, AI Implementation and Confidence

Drawing on insights from over 2,000 librarians representing academic, national and public libraries globally, the report offers an up-to-date view of how they are adapting to rapid change London, U.K.,…

News October 29, 2025
Clarivate Reports Third Quarter 2025 Results

— Continued acceleration of organic ACV — — Raises 2025 Revenues Outlook — — Repurchased 11.7 million ordinary shares and repaid $100 million of debt in the third quarter—  …

Related resources

Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center
The trends to watch in 2025 The trends to watch in 2025
Blog January 8, 2025
The trends to watch in 2025